market access

Views & Analysis

Improving Europe’s pharmaceutical regulatory framework

Innovation and access: Improving Europe’s pharmaceutical reg...

EMA “lags behind” other international regulators when it comes to approval timelines, finds EFPIA analysis.

Market Access

Are we measuring what matters most on uptake to medicines in...

In the second of a two-part series, Leela Barham argues that whilst international comparisons of uptake are useful, there could be more to gain from looking at more medicines and their upta

Market Access

Getting better at measuring international uptake of medicine...

In part one of a two-piece series, Leela Barham looks at whether we are getting better at measuring international uptake of medicines.

Partner Content

Partner Content

Patient and market insights from leading KOLs and life scien...

Insights from leading KOLs in new Dermatology eBook

Sales & Marketing

Sustained healthcare systems need sustainable pharma busines...

COVID-19 demonstrated the importance of robust supply chains and the dangers of an over reliance on overseas manufacturing.

News

Scotland backs Cabometyx combo for kidney cancer, amid stall...

Patients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb's immunotherapy Opdivo with Ipsen's targeted drug Cabometyx, ahead o